康美 CNMD 深 滬
已收盤 02-06 16:00:00 美东时间
41.52
+0.860
+2.12%
華盛通- 最 高41.65
- 今 開40.48
- 成交量 49.75万股
- 最 低 40.17
- 昨 收 40.66
- 總市值 12.86亿
- 52周最高 64.27
- 市盈率 靜 27.50
- 換手率 1.61%
- 52周最低 35.37
- 委 比 -20.00%
- 總股本 3096.80万
- 歷史最高 155.91
- 量 比 0.75
- 振 幅 3.64%
- 歷史最低 11.01
- 每 手 1
- 風險率 7.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Meta 、IBM、拉姆研究、布林克国际等获多家机构上调目标价；微软、特斯拉、ServiceNow、自动数据处理等遭多家下调评级
今日重点评级关注：Piper Sandler：上调Korro Bio评级至"超配"，目标价从11美元升至30美元；Piper Sandler：维持Nurix Therapeutics"超配"评级，目标价从32美元升至35美元
01-30 17:38
Wells Fargo Maintains Equal-Weight on Conmed, Raises Price Target to $42
Wells Fargo analyst Vik Chopra maintains Conmed (NYSE:CNMD) with a Equal-Weight and raises the price target from $41 to $42.
01-29 22:11
Needham Reiterates Hold on Conmedto Hold
Needham analyst Mike Matson reiterates Conmed (NYSE:CNMD) from Hold to Hold.
01-29 18:51
财报速睇 | 康美 2025财年Q4营收3.73亿美元，同比增长7.9%；归母净利润0.17亿美元，同比下滑50.4%
华盛资讯1月29日讯，康美公布2025财年Q4业绩，公司Q4营收3.73亿美元，同比增长7.9%，归母净利润0.17亿美元，同比下滑50.4%。
01-29 14:34
CONMED Q4 international revenue rises 17.0% to USD 163.5 million
CONMED Q4 international revenue rises 17.0% to USD 163.5 million CONMED Corporation (NYSE: CNMD) reported its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. For Q4 2025, sales reached USD 373.2 million, representing a 7.9 percent increase. Domestic revenue
01-29 05:06
A Glimpse of Conmed's Earnings Potential
Conmed (NYSE:CNMD) is gearing up to announce its quarterly earnings on Wednesda...
01-28 04:01
CONMED announces departure of CFO Todd Garner
CONMED (CNMD) on Thursday announced the departure of Todd Garner from his role as Chief Financial Officer effective March 15, 2026. To ensure a smooth and orderly transition, Garner will remain with t...
01-09 06:00
CONMED CFO Todd Garner To Step Down Effective March 15, 2026; Co. Reaffirms Full-Year 2025 Revenue and Adjusted EPS Outlook
CONMED Corporation (NYSE:CNMD) today announced the departure of Todd Garner from his role as Chief Financial Officer effective March 15, 2026. To ensure a smooth and orderly transition, Mr. Garner will remain with the
01-09 05:57
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
Conmed Intends To Exit Its Gastroenterology Product Lines As Part Of Its Broader Portfolio Optimization Strategy
Financial Considerations Related to the ExitGastroenterology product lines are expected to generate $90 million to $95 million in revenue in 2025 with gross margins of approximately 45%.As a result of this strategic
2025-12-05 21:08
